Reverse hydroxamate-based selective TACE inhibitors

被引：30

作者：

Kamei, N ^{[1
]}

Tanaka, T ^{[1
]}

Kawai, K ^{[1
]}

Miyawaki, K ^{[1
]}

Okuyama, A ^{[1
]}

Murakami, Y ^{[1
]}

Arakawa, Y ^{[1
]}

Haino, M ^{[1
]}

Harada, T ^{[1
]}

Shimano, M ^{[1
]}

机构：

[1] Kaken Pharmaceut Co Ltd, Yamashina Ku, Kyoto 6078042, Japan

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2004年 / 14卷 / 11期

关键词：

D O I：

10.1016/j.bmcl.2004.03.048

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Reverse hydroxamate-based selective TACE inhibitors are described. They have potent TACE inhibitory activities and excellent selectivities against MMP-1, 2, 3, 8, 9, 13, 14, and 17. One representative compound, 18 has demonstrated an excellent oral inhibitory activity of the lipopolysaccharide (LPS)-stimulated TNF-alpha production in rats. (C) 2004 Elsevier Ltd. All rights reserved.

引用

页码：2897 / 2900

页数：4

共 37 条

[1] A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells [J].

Black, RA ;

Rauch, CT ;

Kozlosky, CJ ;

Peschon, JJ ;

Slack, JL ;

Wolfson, MF ;

Castner, BJ ;

Stocking, KL ;

Reddy, P ;

Srinivasan, S ;

Nelson, N ;

Boiani, N ;

Schooley, KA ;

Gerhart, M ;

Davis, R ;

Fitzner, JN ;

Johnson, RS ;

Paxton, RJ ;

March, CJ ;

Cerretti, DP .

NATURE, 1997, 385 (6618) :729-733

[2] NOVEL INDOLACTAM-BASED INHIBITORS OF MATRIX METALLOPROTEINASES [J].

CASTELHANO, AL ;

BILLEDEAU, R ;

DEWDNEY, N ;

DONNELLY, S ;

HORNE, S ;

KURZ, LJ ;

LIAK, TJ ;

MARTIN, R ;

UPPINGTON, R ;

YUAN, ZY ;

KRANTZ, A .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (13) :1415-1420

[3] Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial [J].

Chaudhari, U ;

Romano, P ;

Mulcahy, LD ;

Dooley, LT ;

Baker, DG ;

Gottlieb, AB .

LANCET, 2001, 357 (9271) :1842-1847

[4] Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-α converting enzyme inhibitors [J].

Cherney, RJ ;

Duan, JJW ;

Voss, ME ;

Chen, LH ;

Wang, L ;

Meyer, DT ;

Wasserman, ZR ;

Hardman, KD ;

Liu, RQ ;

Covington, MB ;

Qian, MX ;

Mandlekar, S ;

Christ, DD ;

Trzaskos, JM ;

Newton, RC ;

Magolda, RL ;

Wexler, RR ;

Decicco, CP .

JOURNAL OF MEDICINAL CHEMISTRY, 2003, 46 (10) :1811-1823

[5] Discovery of N-hydroxy-2-(2-oxo-3-pyrrolidinyl)acetamides as potent and selective inhibitors of tumor necrosis factor-α converting enzyme (TACE) [J].

Duan, JJW ;

Lu, ZH ;

Xue, CB ;

He, XH ;

Seng, JL ;

Roderick, JJ ;

Wasserman, ZR ;

Liu, RQ ;

Covington, MB ;

Magolda, RL ;

Newton, RC ;

Trzaskos, JM ;

Decicco, CP .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2003, 13 (12) :2035-2040

[6] Anti-TNFα therapy of rheumatoid arthritis:: what have we learned? [J].

Feldmann, M ;

Maini, RN .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :163-196

[7] Pharmacodynamic and pharmacokinetic response to anti-tumor necrosis factor-α monoclonal antibody (infliximab) treatment of moderate to severe psoriasis vulgaris [J].

Gottlieb, AB ;

Masud, S ;

Ramamurthi, R ;

Abdulghani, A ;

Romano, P ;

Chaudhari, U ;

Dooley, LT ;

Fasanmade, AA ;

Wagner, CL .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2003, 48 (01) :68-75

[8] MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover [J].

Holmbeck, K ;

Bianco, P ;

Caterina, J ;

Yamada, S ;

Kromer, M ;

Kuznetsov, SA ;

Mankani, M ;

Robey, PG ;

Poole, AR ;

Pidoux, I ;

Ward, JM ;

Birkedal-Hansen, H .

CELL, 1999, 99 (01) :81-92

[9] Tumor necrosis factor-α monoclonal antibody, infliximab, used to manage severe sciatica [J].

Karppinen, J ;

Korhonen, T ;

Malmivaara, A ;

Paimela, L ;

Kyllönen, E ;

Lindgren, KA ;

Rantanen, P ;

Tervonen, O ;

Niinimäki, J ;

Seitsalo, S ;

Hurri, H .

SPINE, 2003, 28 (08) :750-753

[10] Etanercept as monotherapy in patients with psoriasis [J].

Leonardi, CL ;

Powers, JL ;

Matheson, RT ;

Goffe, BS ;

Zitnik, R ;

Wang, A ;

Gottlieb, AB ;

Bagel, J ;

Camisa, C ;

Caro, I ;

DiGiovanna, JJ ;

Dunlap, FF ;

Elewski, BE ;

Gribetz, CE ;

Farber, HF ;

Feldman, SR ;

Frankel, EH ;

Gaspari, AA ;

Goodman, JJ ;

Gordon, KB ;

Hampel, FC ;

Herdener, RS ;

Hoffman, MD ;

Humeniuk, JM ;

Johnson, SM ;

Kang, S ;

Kimball, AB ;

Kirsner, RS ;

Korman, NJ ;

Krueger, GG ;

Kuwahara, RT ;

Lebwohl, M ;

Ling, MR ;

Liu, DC ;

Lowe, N ;

McCall, CO ;

Menter, A ;

Miller, BH ;

Moore, JK ;

Nayak, AS ;

Ratner, PH ;

Savin, RC ;

Shupack, JL ;

Smith, SL ;

Stone, SP ;

Swinehart, JM ;

Taborn, J ;

Tschen, EH ;

Weinstein, GD ;

Werth, VP .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :2014-2022

← 1 2 3 4 →